Welcome to our dedicated page for Jaguar Health SEC filings (Ticker: JAGX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Jaguar Health, Inc. (NASDAQ: JAGX) SEC filings page on Stock Titan aggregates the company’s regulatory disclosures, giving investors structured access to its capital markets activity and material agreements. Jaguar is a commercial-stage pharmaceuticals company focused on plant-based prescription medicines for gastrointestinal distress in humans and animals, and its filings provide insight into how it finances and supports these programs.
Recent Form 8-K filings describe a range of transactions, including secured and unsecured promissory notes, royalty interest agreements and amendments, PIPE financings involving Series N Perpetual Preferred Stock and common stock with pre-funded warrants, and privately negotiated exchanges of preferred stock for common shares and pre-funded warrants. Other 8-Ks outline at-the-market offering amendments, conditional approval-related developments for Canalevia-CA1, and note purchase agreements backed by deposit account control arrangements and subsidiary guarantees.
Jaguar’s proxy materials, such as definitive proxy statements on Schedule 14A, detail stockholder proposals to approve share issuances under Nasdaq Listing Rule 5635(d), including common stock issuable upon exchange of Series L, Series M, and Series N preferred stock and upon conversion of certain convertible promissory notes and related warrants. These documents also explain voting rights, voting caps for preferred series, and the structure of special and annual meetings.
On this page, users can review Jaguar’s 10-K and 10-Q reports (when available) for broader business and risk disclosures, while Form 4 and related ownership filings provide visibility into insider equity transactions. Stock Titan enhances these filings with AI-powered summaries that highlight key terms in complex documents, such as interest rates, maturity dates, collateral arrangements, voting provisions, and share issuance conditions. Real-time updates from EDGAR ensure that new Jaguar Health filings, including 8-Ks announcing material events, are quickly accessible with plain-language explanations.
Jaguar Health (JAGX) called a Special Meeting for December 8, 2025 to seek stockholder approval under Nasdaq Rule 5635(d) for two financing-related items and a potential adjournment. Proposal 1 asks to approve issuing Common Stock upon exchange and/or redemption of 950.8 shares of Series N Preferred Stock. Based on a $2,500 stated value and a $1.20 exchange price, up to 1,980,827 Exchange Shares (or 1,980,833 Forced Redemption Shares) could be issued, which the company notes would have exceeded 20% of shares outstanding before issuance.
Proposal 2 seeks approval for the September 2025 private placement: 161,583 New PIPE Shares at $1.56 per share and a Pre-Funded PIPE Warrant for up to 479,442 shares (exercise price effectively $1.5599) with a Beneficial Ownership Limitation of 4.99% (increasable to 19.99%). As of October 31, 2025, 3,735,835 Common shares were outstanding. The company highlights potential dilution from issuances tied to Series N exchanges/redemptions and the PIPE, and seeks Proposal 3 authority to adjourn if more time is needed to solicit votes.
Jaguar Health (JAGX) called a Special Meeting on December 8, 2025 to seek stockholder approval under Nasdaq Listing Rule 5635(d) for two financing-related issuances and a potential adjournment.
Proposal 1: Approve issuing Common Stock upon exchange and/or redemption of previously issued Series N Preferred Stock. Based on a fixed $1.20 Exchange Price and 950.8 Series N shares outstanding, up to 1,980,827 Exchange Shares (or 1,980,833 Forced Redemption Shares) could be issued. Shares outstanding were 3,734,635 as of October 17, 2025. Series N was sold for approximately $2.38 million on September 10, 2025. Series N cannot vote on Proposal 1.
Proposal 2: Approve the New PIPE Securities from September 29, 2025: 161,583 New PIPE Shares and a pre-funded warrant for up to 479,442 shares. Combined, these represent about 17.16% of Common Stock outstanding prior to exercise as of October 17, 2025. The warrant includes a 4.99% Beneficial Ownership Limitation, adjustable up to 19.99%.
Proposal 3: Allow adjournment to solicit additional proxies if needed.
Jaguar Health, Inc. filed a Form D notice reporting a Regulation D exempt offering under Rule 506(b) for equity and related option/warrant securities. The filing lists a total offering amount of $1,000,000, with $1,000,000 sold and $0 remaining, indicating the offering has been fully sold. The notice records one investor as having invested and states the issuer accepts a minimum investment of $0. No sales commissions or finders’ fees were paid or estimated, and no proceeds were allocated to executive officers or directors. The filing identifies the issuer as a Delaware corporation with principal offices in San Francisco, California and is signed by Lisa A. Conte, President & CEO on 2025-10-10.
Jaguar Health, Inc. entered into a privately negotiated exchange with a holder of a royalty interest. The company issued 286,532 shares of common stock in exchange for a $600,000 reduction in the outstanding balance of that royalty interest, effectively using equity to reduce this obligation.
The common shares were issued without registration under the Securities Act, relying on the exemption provided by Section 3(a)(9), which allows exchanges of securities with existing holders. The terms of the exchange follow a previously used form of Exchange Agreement that the company had filed in an earlier quarterly report.
Jaguar Health, Inc. (JAGX) filed an S-3 shelf registration describing recent financings, intellectual property and product updates tied to its crofelemer franchise and related assets. The filing references a New Private Placement dated September 28, 2025 that issued New PIPE Shares and a Pre-Funded Warrant, and notes a concurrent private placement that closed on May 22, 2025 which included unregistered warrants to purchase 492,612 shares at an exercise price of $5.84 per share.
Clinical and commercial developments disclosed include ongoing investigator-initiated trials (IITs) and placebo-controlled studies of crofelemer for rare GI conditions, with initial Abu Dhabi IIT results showing reductions in total parenteral nutrition by up to 27% in an MVID patient and up to 12.5% in an SBS-IF patient. An abstract was accepted for presentation at NASPGHAN on November 5-8, 2025. The filing also notes that Canalevia-CA1 (crofelemer delayed-release tablets) is conditionally approved for chemotherapy-induced diarrhea in dogs and is commercially available through multiple US veterinary distributors. The document lists numerous certificates of designation for preferred stock series and describes exchange limits and beneficial ownership caps (commonly 19.99% limits) tied to Series N Preferred Stock and certain pre-funded warrants.
Jaguar Health, Inc. entered into a private placement with Brown Stone Capital Limited to issue securities on September 28, 2025. The company agreed to sell 161,583 shares of voting common stock and 479,442 pre-funded warrants exercisable for common stock. The Securities were offered under Rule 506 of Regulation D to an accredited investor. The filing includes a Securities Purchase Agreement and a Pre-Funded Warrant dated September 28, 2025, and is signed by CEO Lisa A. Conte on behalf of Jaguar Health.
Jaguar Health, Inc. (JAGX) filed a Form D Notice reporting a completed private equity offering under Rule 506(b) that raised $2,377,000. The filing identifies the issuer as a Delaware corporation with its principal place of business in San Francisco, CA. The offering sold all securities (Total Amount Sold: $2,377,000; Total Remaining to be Sold: $0) to a total of 15 investors. The minimum investment accepted was listed as $0. No sales commissions or finders' fees were reported, and no proceeds were allocated to named officers, directors or promoters.
Jaguar Health, Inc. filed an 8-K reporting a material event and attached corporate documents. The filing includes a Certificate of Designation of Preferences, Rights and Limitations of Series N Perpetual Preferred Stock, a Form of Securities Purchase Agreements, and an embedded Cover Page Interactive Data File within the inline XBRL document. The text defines a "Fundamental Transaction" to include transactions such as a sale, merger, consolidation, transfer of substantially all assets, sale or spin-off of subsidiaries, or any transaction where another person/group acquires more than 50% of outstanding common stock. The filing is signed by Lisa A. Conte, Chief Executive Officer & President and dated September 11, 2025.
Lincoln Alternative Strategies LLC filed a Form 3 reporting initial beneficial ownership in Jaguar Health, Inc. (JAGX). The filing states the reporting person holds 600,000 shares of Common Stock as a direct owner. The filing identifies the reporting persons relationship to the issuer as a Director and 10% owner. The statement is dated 08/28/2025 with a signature dated 08/29/2025.
Lincoln Alternative Strategies LLC disclosed ownership of 600,000 shares of Jaguar Health, Inc., representing 18.92% of the outstanding common stock based on 3,171,566 shares as of August 28, 2025. The filing shows Lincoln holds sole voting and sole dispositive power over all 600,000 shares. The Schedule 13G lists the issuer's and filer’s addresses and identifies the filer as a Delaware entity. The filer also certifies the shares were not acquired to change or influence control of the issuer.